ストックスクリーナーアプリを入手
23.62
1.89%
-0.465
前日終値:
$24.09
開ける：
$24.09
24時間の取引高:
41.13M
Relative Volume:
0.98
時価総額：
$134.32B
収益：
$63.83B
当期純損益:
$10.77B
株価収益率:
12.57
EPS:
1.88
ネットキャッシュフロー:
$12.44B
1週間 パフォーマンス:
-2.13%
1か月 パフォーマンス:
-5.99%
6か月 パフォーマンス:
-7.50%
1年 パフォーマンス:
-18.30%
1日の値動き範囲:
$23.62
$24.15
1週間の範囲:
$23.62
$24.80
52週間の値動き範囲:
$20.91
$30.43
Pfizer Inc Stock (PFE) Company Profile
PFE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
23.62 | 136.96B | 63.83B | 10.77B | 12.44B | 1.88 |
|
LLY
Lilly Eli Co
|
712.40 | 665.04B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
176.94 | 425.53B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
218.77 | 388.63B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
122.35 | 238.11B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
77.76 | 199.00B | 63.43B | 16.42B | 14.72B | 6.49 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-25 | 再開されました | Citigroup | Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-08-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | ダウングレード | Argus | Buy → Hold |
| 2024-02-23 | 開始されました | Guggenheim | Buy |
| 2024-01-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-10-16 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-17 | 繰り返されました | JP Morgan | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-06-29 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | ダウングレード | UBS | Buy → Neutral |
| 2023-01-17 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-12-13 | アップグレード | Goldman | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-20 | 繰り返されました | Cowen | Outperform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-13 | アップグレード | UBS | Neutral → Buy |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-06 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | アップグレード | DZ Bank | Hold → Buy |
| 2020-12-16 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 再開されました | Goldman | Neutral |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-10-12 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-16 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-27 | アップグレード | Standpoint Research | Hold → Buy |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-07-30 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 再開されました | Morgan Stanley | Overweight |
| 2019-02-20 | 再開されました | Citigroup | Neutral |
| 2019-01-31 | アップグレード | Argus | Hold → Buy |
| 2019-01-31 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | ダウングレード | UBS | Buy → Neutral |
| 2018-12-11 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-11-01 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
すべてを表示
Pfizer Inc (PFE) 最新ニュース
Pfizer, BioNTech Challenge GSK Patents Over Vaccine Tech - Law360
Can a multibillion-dollar deal put Pfizer in the obesity big leagues? - PharmaVoice
November 7th Options Now Available For Pfizer (PFE) - Nasdaq
Does This Acquisition Make Pfizer Stock a Great Buy? - Nasdaq
Geriatric Medicines Market Set for Dynamic Growth with Key - openPR.com
Pfizer to showcase cancer drug data at ESMO Congress 2025 By Investing.com - Investing.com Canada
Essex Financial Services Inc. Purchases 29,086 Shares of Pfizer Inc. $PFE - MarketBeat
Ruffer LLP Sells 792,785 Shares of Pfizer Inc. $PFE - MarketBeat
MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH Decreases Stock Position in Pfizer Inc. $PFE - MarketBeat
Pfizer to showcase cancer drug data at ESMO Congress 2025 - Investing.com
Pfizer Highlights Momentum in Redefining Standards of Care in Cancer at ESMO 2025 - Business Wire
Pfizer Inc. $PFE Shares Purchased by Penn Davis Mcfarland Inc. - MarketBeat
Pfizer Tries to Fatten Its Profits With Weight Loss Drugs - Investing.com
Xcel Wealth Management LLC Reduces Stock Position in Pfizer Inc. $PFE - MarketBeat
Santori & Peters Inc. Purchases 11,000 Shares of Pfizer Inc. $PFE - MarketBeat
TD Private Client Wealth LLC Grows Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Sheets Smith Wealth Management Sells 27,150 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering. - Yahoo Finance
Pfizer Agrees to Take Over Metsera for $4.9 Billion - CHEManager
Pneumococcal Vaccine Market Opportunities and Strategies to 2034 - GlobeNewswire Inc.
Pfizer Inc: Is Wall Street Wrong to Give Up on This Comeback Story? - Yahoo Finance
Dividend Stock Portfolio for Retirement: Pfizer’s (PFE) Reliable Payouts - Yahoo Finance
Pfizer boosts push for obesity treatments with $4.9B deal for Metsera - LiveNOW from FOX
Pfizer: Jefferies raises target price - MarketScreener
Foster Victor Wealth Advisors LLC Has $16.48 Million Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Sold by Public Employees Retirement System of Ohio - MarketBeat
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead? - AOL.com
78,922 Shares in Pfizer Inc. $PFE Bought by IMS Capital Management - MarketBeat
With 67% institutional ownership, Pfizer Inc. (NYSE:PFE) is a favorite amongst the big guns - Yahoo Finance
Jefferies Adjusts Price Target on Pfizer to $34 From $33, Maintains Buy Rating - MarketScreener
Arvinas stock downgraded by BofA as Pfizer partnership shifts - Investing.com
Wilsey Asset Management Inc. Has $23.88 Million Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Sold by Fifth Third Bancorp - MarketBeat
Pfizer to buy obesity drug maker Metsera - Medical Dialogues
17,033 Shares in Pfizer Inc. $PFE Acquired by Revisor Wealth Management LLC - MarketBeat
Autozone, Pfizer, Valley National Bancorp - TradingView
Where Will Pfizer Be in 5 Years? - Nasdaq
PFIZER INC : Receives a Buy rating from Jefferies - MarketScreener
Pfizer bets on weight-loss drugs - Global Cosmetics News
Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts - BioSpace
Pfizer Challenges Novo Nordisk and Eli Lilly with $7.3B Metsera Buyout - NAI500
How Pfizer Inc. (PFE) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Pfizer Raises EPS Guidance and Expands Cost-Cutting Plan While Boosting Dividend Appeal - Yahoo Finance
Pfizer Inc. (PFE) Targets $4.5B in Cost Savings to Fuel R&D and Innovative Therapies - Yahoo Finance
Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock? - Yahoo Finance
Pfizer’s Acquisition Of Metsera Bucks The Recent Trend For Obesity Deals - insights.citeline.com
Wachtell, Paul Weiss guide Pfizer’s $7.3bn buy of weight loss drugmaker Metsera - The Global Legal Post
Pfizer’s $5B Bet on Metsera ($MTSR) vs Viking Therapeutics ($VKTX) - MSN
Metsera (MTSR) Soars to All-Time High on $7.3-Billion Merger With Pfizer - MSN
Pfizer's $7.3B Gamble: Chasing Ozempic Rivals After Own Weight-Loss Pill Flopped - Yahoo Finance
Pfizer (PFE): Is This Healthcare Giant’s Valuation Now Too Low to Ignore? - simplywall.st
Pfizer Inc (PFE) 財務データ
収益
当期純利益
現金流量
EPS
1.97%
大文字化:
|
ボリューム (24 時間):